No Data
Navigating Uncertainty: Tectonic Therapeutic's Clinical Data Volatility and Its Impact on Business Stability
Tectonic Therapeutic Director Buys Shares Worth Over $1.4 Million
Here's Why We're Not Too Worried About Tectonic Therapeutic's (NASDAQ:TECX) Cash Burn Situation
Tectonic Therapeutic Up Nearly 11%, on Track for Highest Close Since February 2022 -- Data Talk
Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans
Piper Sandler Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $76
Piper Sandler analyst Yasmeen Rahimi maintains $Tectonic Therapeutic(TECX.US)$ with a buy rating, and maintains the target price at $76.According to TipRanks data, the analyst has a success rate of 40
No Data
No Data